Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics Inc (FATE)
:FATE
Holding FATE?
Track your performance easily
FATE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.04 - $8.83
Previous CloseN/A
Volume630.90K
Average Volume (3M)3.30M
Market Cap
$142.37M
Enterprise Value$214.25M
Total Cash (Recent Filing)$92.11M
Total Debt (Recent Filing)$2.50M
Price to Earnings (P/E)―
Beta3.35
Next Earnings
Mar 03, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding113,894,330
10 Day Avg. Volume3,096,537
30 Day Avg. Volume3,303,223
Standard Deviation0.26
R-Squared0.17
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.18
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue15.93
Enterprise Value/Gross Profit3.37
Enterprise Value/Ebitda-1.32
Forecast
1Y Price Target
$5.50Price Target Upside340.00% Upside
Rating ConsensusHold
Number of Analyst Covering12
Fate Therapeutics News
PremiumCompany Announcements
Fate Therapeutics Announces Executive Leadership Transition
PremiumCompany Announcements
Fate Therapeutics Announces Leadership Transition for 2025
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsA compelling clinical signal for FT819 in their first treated patient with refractory lupus nephritis, achieving complete clinical remission without any CRS or ICANS.
Financial PerformanceFATE reported 3Q24 operating results with a net loss per share better than the consensus estimate.
Regulatory ProgressThe FDA has allowed FATE's IND application to initiate a Phase 1 study for FT522 in B-cell mediated autoimmune diseases.
Bears Say
Clinical TrialsThe repopulation of B cells in FATE's study appears faster than in autologous CAR T studies, raising concerns about the durability of the treatment.
Financial PerformanceReturn on Equity is notably negative, indicating the company is currently not profitable.
Regulatory TimelinesPotential regulatory timelines for FATE programs have been pushed to 2027+, as lead programs remain in early stages of development.
---
Ownership Overview
18.49% Insiders
16.27% Mutual Funds
0.35% Other Institutional Investors
54.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FATE FAQ
What was Fate Therapeutics Inc’s price range in the past 12 months?
Fate Therapeutics Inc lowest stock price was $1.04 and its highest was $8.83 in the past 12 months.
What is Fate Therapeutics Inc’s market cap?
Fate Therapeutics Inc’s market cap is $142.37M.
When is Fate Therapeutics Inc’s upcoming earnings report date?
Fate Therapeutics Inc’s upcoming earnings report date is Mar 03, 2025 which is in 44 days.
How were Fate Therapeutics Inc’s earnings last quarter?
Fate Therapeutics Inc released its earnings results on Nov 12, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.416 by $0.016.
Is Fate Therapeutics Inc overvalued?
According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued.
Does Fate Therapeutics Inc pay dividends?
Fate Therapeutics Inc does not currently pay dividends.
What is Fate Therapeutics Inc’s EPS estimate?
Fate Therapeutics Inc’s EPS estimate is -0.44.
How many shares outstanding does Fate Therapeutics Inc have?
Fate Therapeutics Inc has 113,894,330 shares outstanding.
What happened to Fate Therapeutics Inc’s price movement after its last earnings report?
Fate Therapeutics Inc reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.416. Following the earnings report the stock price went down -8.824%.
Which hedge fund is a major shareholder of Fate Therapeutics Inc?
Among the largest hedge funds holding Fate Therapeutics Inc’s share is Deerfield Management Company, LP. It holds Fate Therapeutics Inc’s shares valued at 12M.
---
Fate Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.50 (340.00% Upside)
$5.50 (340.00% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $63.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.28%
12-Months-Change
Fundamentals
Return on Equity
-46.59%
Trailing 12-Months
Asset Growth
-8.98%
Trailing 12-Months
Company Description
Fate Therapeutics Inc
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
---
FATE Earnings Call
Q1 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials, particularly with FT819 and FT522, alongside a strong financial position. However, revenue growth remains limited and operating expenses are high, suggesting a balanced outlook with promising clinical achievements countered by financial challenges.Read More>---
FATE Stock 12 Month Forecast
Average Price Target
$5.50
▲(340.00% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Beam Therapeutics
―
Sangamo Biosciences
―
Best Analysts Covering FATE
1 Year
1 Year Success Rate
3/15 ratings generated profit
1 Year Average Return
-23.64%
assigned a buy rating 4 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -23.64% per trade.
---